News Releases
- September 7, 2010
ISOTECHNIKA PHARMA ANNOUNCES PARTIAL CONVERSION OF CONVERTIBLE DEBENTURE
EDMONTON, Sept. 7 /CNW/ - Isotechnika Pharma Inc. announces it has received a notice to convert from 3SBio Inc. with respect to the convertible debenture previously issued to 3SBio Inc. on August 23, 2010. Under the ...
- August 24, 2010
EDMONTON, Aug. 24 /CNW/ - Isotechnika Pharma Inc. ("Isotechnika") (TSX: ISA), a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc. ("3SBio") (NASDAQ: SSRX), a ...
- August 11, 2010
Isotechnika reports second quarter 2010 financial results
Trades on Toronto Stock Exchange - (TSX:ISA) EDMONTON, Aug. 11 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA) today announced financial results for the second quarter ended June 30, 2010. ...
- August 4, 2010
Lux Biosciences receives Complete Response letter from FDA for voclosporin
Trades on Toronto Stock Exchange - (TSX:ISA) EDMONTON, Aug. 4 /CNW/ - Isotechnika Pharma Inc. today announced that their partner, Lux Biosciences, Inc., has received a Complete Response letter ...
- June 23, 2010
FDA further clarifies Lux Biosciences' Advisory Committee meeting cancellation
EDMONTON, June 23 /CNW/ - Isotechnika Pharma Inc. is providing the following information as a follow-up to the news release issued this morning. The U.S. Food and Drug Administration (FDA) has posted additional information ...
EDMONTON, June 23 /CNW/ - Isotechnika Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has cancelled the Dermatology and Ophthalmology Drugs Advisory Committee review of partner, Lux Biosciences', ...
- May 12, 2010
Isotechnika reports first quarter 2010 financial results
EDMONTON, May 12 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA) today announced highlights and financial results for the first quarter ended March 31, 2010. ...
- May 11, 2010
Isotechnika partner announces advisory committee date for voclosporin
EDMONTON, May 11 /CNW/ - Isotechnika Pharma Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review partner, Lux Biosciences', ...
- March 30, 2010
New drug application for voclosporin accepted for priority review by FDA
EDMONTON, March 30 /CNW/ - Isotechnika Pharma Inc. (TSX: ISA) today announced that the New Drug Application (NDA) for the Company's next generation calcineurin inhibitor, voclosporin, has been accepted for priority ...
- March 24, 2010
Isotechnika reports full year and fourth quarter 2009 financial results
EDMONTON, March 24 /CNW/ - (ISA:TSX): Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific ...